238 related articles for article (PubMed ID: 30550358)
1. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
[TBL] [Abstract][Full Text] [Related]
4. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
[TBL] [Abstract][Full Text] [Related]
5. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
6. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
8. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Brufsky A; Kennedy L; Bhatta S; Bhowmik D; Buchanan J; Despiegel N; Hechmati G
J Med Econ; 2020 Jan; 23(1):37-47. PubMed ID: 31364885
[No Abstract] [Full Text] [Related]
10. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
13. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
14. [Bone and calcium metabolism associated with malignancy. Bone and calcium metabolism associated with malignancy.].
Ishikawa T
Clin Calcium; 2018; 28(11):1431-1440. PubMed ID: 30373998
[TBL] [Abstract][Full Text] [Related]
15. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.
Body JJ; von Moos R; Rider A; Hallworth P; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2019 Feb; 14():100212. PubMed ID: 30627511
[TBL] [Abstract][Full Text] [Related]
16. The role of bone-targeted therapies for prostate cancer in 2017.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2017 Sep; 11(3):216-224. PubMed ID: 28644302
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
18. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
Huang SY; Yoon SS; Shimizu K; Chng WJ; Chang CS; Wong RS; Gao S; Wang Y; Gordon SW; Glennane A; Min CK
Adv Ther; 2020 Jul; 37(7):3404-3416. PubMed ID: 32524500
[TBL] [Abstract][Full Text] [Related]
19. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.
Jayan A; Raghavendra AS; Bassett R; Barcenas CH
Clin Breast Cancer; 2023 Dec; 23(8):e515-e522. PubMed ID: 37735019
[TBL] [Abstract][Full Text] [Related]
20. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]